NKTX
Nkarta, Inc.
$3.22
+0.37 (+12.98%)
At close · Jul 2
Market Cap
$230.38M
Shares
71,545,358
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.22
Open$2.87
Day$2.82–3.28
52W$1.68–3.65
Avg vol 30d581K
Short int3.5M · 4.8% float · 6.4d
Short vol40%
Last earningsMay 12, 2026
DataJul 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+38% above
+
Price vs 50-day avg
+11% above
◦
RSI (14)
62 · neutral
+
MACD trend
positive
◦
52-week position
78% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $3 › 200d $2 — 50d above 200d
+
Institutional flow
+5% holders QoQ · +18 funds added
−
Insider flow
Net -$4.8K over 90 days · 100% sells
+
Short interest
4.83% of float · ▼ -33.9% MoM · 6.4 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
125 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+12% Y/Y
−
Free cash flow
$-89.9M
+
Balance sheet
net cash $39.6M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+38% above
Bullish
Price vs 50-day avg
+11% above
Bullish
RSI (14)
62 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
78% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +18 funds added
Insider flow
Distributing
Net -$4.8K over 90 days · 100% sells
Short interest
Falling
4.83% of float · ▼ -33.9% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
125 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 78%
52-wk high $4
vs 200-day avg +38%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NKTX
this stock
Nkarta, Inc.
|
$230.38M | +74.1% | — | — | 4.8% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NKTX | +15.8% | +18.4% | +52.6% | +13.8% | +74.1% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +14.4% | +19.6% | +44.6% | +14.1% | +64.8% |